o 20 years experience in the field of mental health and addiction and is currently the medical director of First Step Addiction Clinics, Sunrise Clinics and the staff physician at the Satellite Comprehensive Opioid Addiction Treatment Centre in Toronto. o Held positions at the University of Toronto and CAMH . For the last decade he has been the Vice Chair of Addiction Medicine for the Ontario Medical Association and has worked as supervisor for the College of Physicians and Surgeons of Ontario. o Previously appointed to a Minister of Health’s Task Force. o Contributed to scientific studies in mental health and was lead author for a recently published paper on patterns of opioid abuse in Ontario. o Associate Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto. o Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing. o BSc in psychology from the University of Toronto and an MA in social psychology from York University while currently undergoing his PhD candidacy at York University. o Main research interests include sustained attention, emotion regulation and creativity which are ostensibly affected by psychedelics. Clinical interests include disorders amenable to psychedelic psychotherapy, including mood disorders and obsessive compulsive disorder. Executive Medical & Clinical Advisory Team 25 P r i v a t e & C o n f i d e n t i a l Chris Sankey, M.D. — Clinic Advisor Thomas Anderson — Clinical Research Advisor Doug Sommerville — Chief Pharmaceutical Strategist Rotem Petranker — Clinical Research Advisor Domenico Fuoco, Ph.D. — SVP Scientific Innovation o Research Director and co-founder of the Psychedelic Studies Research Program (PSRP) at the University of Toronto. o Co-Founder of the Toronto Centre for Psychedelic Science which has published some of the first academic research on microdosing. o PhD candidate and cognitive neuroscientist with the Regulatory and Affective Dynamics (RAD) Lab of Norman Farb, an associate professor of psychology at U of T Mississauga. o Thomas’ research is some of the first on psychedelic microdosing. o Supported by the Natural Sciences and Engineering Council of Canada (NSERC) and the Stratas Foundation which recently awarded Thomas with an innovation award. o Former Country Head and Global SVP at Teva Canada, with record revenue exceeding $1.4B - more than 5 billion doses GMP production. o 25 years experience in pharma business development, R&D, M&A in domestic and international medical markets. o Past Chair of the Canadian Generic Pharmaceutical Association — $6B industry sales. o Former Global Vice President at Baxter Healthcare Corporation. o Chemistry background with continued studies that lead to a doctorate in pharmacy at the Universita deali studi di Perugia, Italy, a PhD of pharmacology and toxicology, followed by a post-doctoral fellowship in supportive and palliative care at McGill University. o Founder of Smart Medicines GMP Inc. with vast experience in the pharmaceutical and cannabis industries. o Successfully invented, patented and sold 4 inventions to major pharmaceutical companies. o Winner of the Dr. Henry Shibata Fellowship award (2015) and the International Year of Biodiversity Chemistry Initiative Award (2010) from the Instituto Italo - Latino Americano.